Piper Sandler Starts Abivax (ABVX) at Overweight, 'Obefazimod Emerging as Highly Competitive IBD Therapy'
Tweet Send to a Friend
Piper Sandler analyst Alexander Potter initiates coverage on Abivax (NASDAQ: ABVX) with a Overweight rating and a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
